Xellia Pharmaceuticals Aps
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Xellia Pharmaceuticals Aps
In an exclusive interview with Generics Bulletin, the CEO of API and FDF manufacturer Xellia Pharmaceuticals, expresses concern over supply chain resilience of the US and the EU, as he points out the weaknesses exposed by the pandemic. The company has also announced the release of its first anti-infectives manufactured at its newly operational Cleveland site.
Kodak, Fujifilm and startups Civica Rx and Phlow fight with grit, vision and government support to restore US pharmaceutical manufacturing.
With a commitment to make drug products affordable and accessible in Europe, Xellia has joined off-patent industry association Medicines for Europe.
With a pipeline of over 35 ANDAs, India's Caplin Steriles plans to launch five generic injectables through a strategic partnership with Xellia Pharma in the US market. Out of the five ANDAs, one has been approved and is ready for launch.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries